Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

SHOCKING: Pascal soriot - What They Never Told You

AstraZeneca to inject £300 million into UK in surprise U-turn

AstraZeneca chief executive Pascal Soriot has thanked the Government ‘for their efforts to improve access for patients’

The Independent UK

AstraZeneca makes surprise U-turn with £300m pharma investment in UK

Drugmaker had stalled large-scale projects in England but has now pledged investment at two sites, announced by Keir Starmer

The Guardian - UK

AstraZeneca boss Pascal Soriot nets £17.7m in pay and bonuses for 2025

The drug maker’s annual report showed his total pay lifted 6.4% last year after he was awarded nearly £16 million in bonuses and share awards.

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

AstraZeneca boss Pascal Soriot’s pay rises to £17.7m

Increase of 6.4% comes as drugmaker reports strong profit growth, despite cancelling UK investment projects

The Guardian - UK

AstraZeneca CEO hails NHS drug price deal but keeps pause on £200m UK investment

Pascal Soriot suggests UK-US agreement will not be enough to revive plan to expand Cambridge site

The Guardian - UK

AstraZeneca profits jump by 40% amid strong demand for cancer drugs

Shares edged 1% higher in morning trading on Tuesday, with the stock having risen 28% in the past six months.

Evening Standard

GSK, take two: the bullish tone at the top is finally more convincing

New boss Luke Miels knows perils of overpromising but there is growing sense pharma firm is closer to filling potential

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Who is on Keir Starmer's China trip, and why are they there?

A delegation of ministers, business leaders and cultural figures are part of the trip, as the Prime Minister seeks to improve relations

Evening Standard

NHS won’t get cutting-edge drugs unless it pays more, says AstraZeneca boss

Pascal Soriot calls for cost-effectiveness thresholds to undergo ‘substantial adjustment based on inflation’

The Guardian - UK

AstraZeneca makes deal with Trump to lower drug prices and avoid tariffs

Company will sell some medicines at a discount to government’s Medicaid health plan in exchange for tariff relief

The Guardian - US

AstraZeneca agrees to lower drug prices for Medicaid under Trump administration deal

AstraZeneca has agreed to lower prescription drug costs for Medicaid under a deal with the Trump administration

The Independent UK

AstraZeneca to upgrade US listing in ‘knock-back for London’

UK’s biggest drugmaker will put its US shares on a par with its London-based stock but says HQ will stay in Cambridge

The Guardian - UK

AstraZeneca pauses £200m expansion in Cambridge

It comes after the pharmaceutical firm abandoned plans to invest £450 million in a vaccine plant in Merseyside earlier this year.

Evening Standard

Top executive pay in UK’s biggest firms hits new record as more take home £10m

Median pay for chief executive officers of FTSE 100 companies was £4.58 million in the 2024-2025 financial year.

Evening Standard

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Top executives’ pay in UK hits record high – reaching 122 times of average worker

It marks the fourth year in a row that chief executives have taken home a record amount

The Guardian - UK

Record salaries for UK chief executives as pay rises for third year in a row

Report finds more than £1bn handed out to just 217 FTSE 100 bosses in the last financial year

The Guardian - UK

Ministers take note: now is the moment to fight to keep AstraZeneca’s listing in London

One hopes cogs are turning in Westminster after Pascal Soriot’s affectionate talk of US at pharmaceutical giant’s half-year results

The Guardian - UK

AstraZeneca chief executive hails ‘vital importance of US’ as Trump tariffs loom

Pascal Soriot refuses to be drawn, however, on reports AZ could move its main stock market listing across the Atlantic

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times

AstraZeneca To Invest $50 Bn In The US As Tariff Threat Looms

British pharmaceutical giant AstraZeneca said Tuesday it would invest $50 billion in the United States by 2030 amid Donald Trump's threats to impose tariffs on the sector.

Fortune

AstraZeneca CEO Pascal Soriot on why he’s building in the U.S.: ‘Europe is losing ground’

Also: All the news and watercooler chat from Fortune.

The Guardian - UK

AstraZeneca to invest $50bn in US by 2030 amid Trump tariff threats

UK company to fund new drug manufacturing facility in Virginia and expand R&D facilities around US

The Guardian - UK

Rachel Reeves vows to stick to fiscal rules and declines to rule out wealth tax – as it happened

Rolling coverage of the latest economic and financial news, as chancellor Rachel Reeves testifies to House of Lords economic affairs committee

The Guardian - UK

If AstraZeneca goes to the US, it will be a major blow for London and Labour

Move would deprive LSE of its biggest star and could topple a key pillar of the government’s industrial strategy

The Independent UK

Fears over £160bn blow to London’s stock market as AstraZeneca considers listing move to US

CEO Pascal Soriot has not hidden his annoyance at taxes and regulations the pharmaceutical firm have to navigate

The Guardian - UK

AstraZeneca boss ‘wants to shift stock market listing to US’

Report claims CEO Pascal Soriot talked in private about moving UK’s most valuable listed company and considered shifting its domicile

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the London Stock Exchange

191 stories

LSE

169 stories

the Natural History Museum

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.